Use of oritavancin for prevention and treatment of anthrax

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9089507
APP PUB NO 20100041585A1
SERIAL NO

12442751

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against B. anthracis. Methods for the treatment, prophylaxis and prevention of B. anthracis infection and disease in animals, including humans, are described.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MELINTA THERAPEUTICS INC300 GEORGE STREET SUITE 301 NEW HAVEN CT 06511

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Moeck, Gregory St. Laurent, CA 8 25
Parr,, Jr Thomas Reeves Indianapolis, US 1 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 28, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00